Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells

被引：34

作者：

Basciani, Sabrina ^{[2
,3
]}

Vona, Rosa ^{[1
]}

Matarrese, Paola ^{[1
]}

Ascione, Barbara ^{[1
]}

Mariani, Stefania ^{[2
]}

Gnessi, Lucio ^{[2
]}

Malorni, Walter ^{[1
]}

Straface, Elisabetta ^{[1
]}

机构：

[1] Ist Super Sanita, Sect Cell Aging & Degenerat, Dept Drug Res & Evaluat, I-0161 Rome, Italy

[2] Univ Roma La Sapienza, Dept Med Physiopathol, Rome, Italy

[3] IRCCS San Raffaele, Dept Med Sci, Cardiovasc Res Unit, Rome, Italy

来源：

FEBS LETTERS | 2007年 / 581卷 / 30期

关键词：

imatinib; Kaposi's sarcoma; drug resistance; apoptosis; autophagy;

D O I：

10.1016/j.febslet.2007.11.069

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Multi drug resistance (MDR) is defined as the ability of tumor cells to become resistant to unrelated drugs. Tyrosine kinase inhibitor imatinib has been demonstrated to be effective in the treatment of certain tumors. In particular, imatinib inhibits Bcr-Abl kinase activity, c-kit and the phosphorylation of platelet-derived growth factor (PDGF) receptors. In this work, we show that imatinib inhibits PDGF phosphorylation not only in wt Kaposi sarcoma (KS) but also in multi drug resistant KS cells. This was associated with an increased apoptosis in wt cells and an increased autophagy in MDR-KS cells. These data add new insights to the possible use of imatinib in the overcoming of MDR in KS cells. (c) 2007 Published by Elsevier B. V. on behalf of the Federation of European Biochemical Societies.

引用

页码：5897 / 5903

页数：7

共 22 条

[1] Imatinib mesylate inhibits Leydig cell tumor growth:: Evidence for in vitro and in vivo activity [J].

Basciani, S ;

Brama, M ;

Mariani, S ;

De Luca, G ;

Arizzi, M ;

Vesci, L ;

Pisano, C ;

Dolci, S ;

Spera, G ;

Gnessi, L .

CANCER RESEARCH, 2005, 65 (05) :1897-1903

[2] Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression [J].

Beppu, K ;

Jaboine, J ;

Merchant, MS ;

Mackall, CL ;

Thiele, CJ .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (01) :46-55

[3] Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment [J].

Brama, Marina ;

Basciani, Sabrina ;

Cherubini, Sara ;

Mariani, Stefania ;

Migliaccio, Silvia ;

Arizzi, Mario ;

Rosano, Giuseppe ;

Spera, Giovanni ;

Gnessi, Lucio .

[4] Physiological functions of Atg6/Beclin 1: a unique autophagy-related protein [J].

Cao, Yang ;

Klionsky, Daniel J. .

CELL RESEARCH, 2007, 17 (10) :839-849

[5] Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].

Capdeville, R ;

Buchdunger, E ;

Zimmermann, J ;

Matter, A .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502

[6] Emerging targets and novel strategies in the treatment of AIDS-related Kaposi's sarcoma: Bidirectional translational science [J].

Dezube, Bruce J. ;

Sullivan, Ryan ;

Koon, Henry B. .

JOURNAL OF CELLULAR PHYSIOLOGY, 2006, 209 (03) :659-662

[7]

Dezube Bruce J, 2004, AIDS Read, V14, P236

[8] Biology of Kaposi's sarcoma [J].

Ensoli, B ;

Sgadari, C ;

Barillari, G ;

Sirianni, MC ;

Stürzl, M ;

Monini, P .

EUROPEAN JOURNAL OF CANCER, 2001, 37 (10) :1251-1269

[9] The anticancer drug imatinib induces cellular autophagy [J].

Ertmer, A. ;

Huber, V. ;

Gilch, S. ;

Yoshimori, T. ;

Erfle, V. ;

Duyster, J. ;

Elsaesser, H-P ;

Schaetzl, H. M. .

LEUKEMIA, 2007, 21 (05) :936-942

[10] Role of KIT and platelet-derived growth factor receptors as oncoproteins [J].

Fletcher, JA .

SEMINARS IN ONCOLOGY, 2004, 31 (02) :4-11

← 1 2 3 →